251

Natalizumab 20mg/mL Infusion

Prescriber Criteria: Consultant Neurologist

Inpatient use:

1. Multiple Sclerosis

As a single-disease modifying therapy in rapidly evolving severe relapsing-remitting multiple sclerosis (RRMS).

RRMS is defined by two or more disabling relapses in one year, and with one or more gadolinium-enhancing lesions on brain magnetic resonance imaging (MRI) or a significant increase in T2 lesion load compared with a previous MRI.

An official approval from the Medicines Approval Section (permit) is required.

Duration of Approval:
1 year